Royalty Pharma Acquires Royalty Interest In Imdelltra From BeOne

(RTTNews) - Royalty Pharma plc (RPRX) has acquired a royalty interest in Amgen's Imdelltra, a DLL3 targeting bispecific T-cell engager, from BeOne Medicines for $885 million upfront. The agreement includes an option for BeOne to sell additional Imdelltra royalties to Royalty Pharma for up to $65 million. BeOne will retain China commercial rights to Imdelltra.

Imdelltra received accelerated approval from the FDA in May 2024 for the treatment of extensive-stage small cell lung cancer in patients who have progressed on or after receiving platinum-based chemotherapy. Amgen is currently enrolling Phase 3 studies for Imdelltra in front-line small cell lung cancer.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.